Object. Over a 16-year period, 570 patients presenting with acute aneurysmal subarachnoid hemorrhage were successfully treated using endosaccular coil embolization within 30 days of hemorrhage by a single surgeon. Patients were followed to assess the stability of aneurysm occlusion and its longer-term efficacy in protecting against rebleeding.
T he past 20 years have been witness to a new medical era, even a revolution in the treatment of intracranial aneurysms. 13, 22 The advent and development of Guglielmi detachable coils in 1990, and its FDA approval in 1995, introduced an alternative to surgical clip ligation for the direct treatment of intracranial aneurysms. 50 It is estimated that approximately 50,000 patients worldwide are now treated each year with detachable coils, 14 and that more than 300,000 patients have been treated using this technique as of 2009. 14, 22 In the past decade, the approach has become the treatment of first choice for most ruptured intracranial aneurysms. 3, 6, 32, 36 For operable aneurysms in the anterior circulation, the ISAT 27 demonstrated improved outcomes 1 year posttreatment for patients treated with coils compared with clips. 29 The goal of treatment following SAH is the promotion of independent patient survival and the prevention of rehemorrhaging and aneurysm regrowth; ISAT also demonstrated an increased risk of late rebleeding in patients randomized and treated by endovascular coil occlusion. 28 Nonrandomized observational studies have shown that 1.2%-2.6% of coil-treated patients experience late rebleeding, usually defined as a hemorrhage occurring more than 30 days after initial treatment. Sixteen-year single-surgeon experience with coil embolization for ruptured intracranial aneurysms: recurrence rates and incidence of late rebleeding
Clinical article
Higher rates of rebleeding among coil-treated patients in the ISAT did not negate the outcome benefit they enjoyed at 1 year, 28 but the study recruited a specific group of patients with SAH, and this conclusion may not apply more generally.
To date there have been no studies reporting recurrence, retreatment, and late rebleeding rates after 15 or more years of follow-up for an unselected cohort of patients treated by a single practitioner. The aim of this paper is to report the long-term follow-up results (clinical and angiographic data obtained in consecutive patients treated with endosaccular coil embolization after aneurysm rupture) to assess the treatment's ability to protect against late rebleeding and to prevent recanalization in the long term.
Methods

Patient Population
During a 16-year period (June 1992-October 2008), 745 consecutive patients underwent EVT for intracranial aneurysms performed by a single surgeon (J.V.B.) in a single center. The clinical and angiographic data for these patients were recorded and collected in a prospective database. 42 A review of this database identified 570 patients who were successfully treated by endosaccular packing with coils acutely after suffering aneurysmal SAH (that is, within 30 days), and who formed the study population. This cohort comprised 379 women (66.5%) and 191 men (33.5%). The mean age of patients at presentation was 53 years (range 21-87 years). The patients' age distributions by decade are shown in Table 1 . In summary, 79 (13.9%) were younger than 40 years of age, 315 (55.3%) were between the ages of 40 and 59 years, and 176 patients (30.9%) were 60 years or older. The other 175 patients admitted during this period were excluded from the study because they were either treated for unruptured aneurysms or underwent surgery more than 30 days after their last SAH. There were no acutely ruptured aneurysms treated by parent artery occlusion or stent placement alone.
Patient Selection
In the study's first 8 years (1992-2000), patients were generally referred with aneurysms unsuitable for neurosurgical clip ligation. Between 1995 and 2002, 40 patients were participants in ISAT who had been randomly assigned to coil treatment (after both coiling and clipping procedures were deemed appropriate). In the past 8 years we have seen a reversal in referral pattern, with endosaccular embolization becoming the treatment of first choice for patients with SAH; a change in referral bias consequent to the ISAT reports. The entry criteria for patients included in the present study were the following: 1) a clinical diagnosis of SAH supported by either CT scanning or a xanthochromic CSF sample; and 2) coil embolization by endosaccular packing performed within 30 days of the last hemorrhage, and which successfully occluded the aneurysm.
Clinical Follow-Up Strategy
Coil embolization was performed as soon as possible after admission to our institution. The procedures were performed within 2 days of aneurysm rupture in 249 patients (43.7%) and within 2 weeks in 495 patients (86.8%) ( Table 2) . Clinical status was recorded using the WFNS 9 grading score at the time of treatment rather than at the time of first admission because of the variability in time spent transferring to our hospital.
Following discharge from the hospital, patients were scheduled a follow-up clinical examination at 6 weeks, and imaging at 6 months postembolization. Initially, until 2004, the latter comprised a catheter angiogram (DS angiography), and further surveillance imaging was performed only if aneurysm occlusion was incomplete, or if substantial or unstable aneurysm remnant filling was identified. Patients showing complete occlusion were thereafter discharged from surveillance imaging.
Since 2004, MR angiography has been used for additional imaging at 24 months postembolization as well as for the first imaging session at 6 months. Currently, DS angiography is reserved for patients whose aneurysms show recurrence and for whom retreatment is anticipated, or when MR imaging is inconclusive or contraindicated. Each time aneurysm regrowth was detected, the protocol would be personalized to reflect the need for more frequent imaging. After aneurysm retreatment, the routine protocol was restarted.
After discharge from the surveillance imaging protocol, patients were contacted by mail and asked to fill out follow-up questionnaires. All patients were contacted by mail in 5-year audits conducted in 1998, 2003, and 2008. The questionnaire design was based on that used in the International Stroke Trial 18 and the ISAT to collect an mRS. This score easily translates to the GOS 19 score as defined by the WFNS, 9 such that mRS Score 0 or 1 equals GOS Score 1, mRS Score 2 equals GOS Score 2, mRS Score 3 or 4 equals GOS Score 3, and mRS Score 5 equals GOS Score 4. Patients who died were assigned a GOS score of 5.
Specific inquiries were made about further intracranial hemorrhages, and patients, families, or their referring physicians were contacted to provide details of the current status for patients who failed to respond to the ques- tionnaire. All reported deaths were subjected to specific inquiry as to the cause. Patients who were judged eligible thus remained in the study until they died, or until surgical clip ligation or arterial occlusion was performed for the management of recurrence or rebleeding.
Imaging Follow-Up Strategy
Treated aneurysms were graded by the degree of occlusion observed on angiography studies obtained at the EOT by the senior author (DS angiography). A 3-point scale was used to replace our original percent-occlusion system, 3 such that 100% occlusion of the aneurysm sac corresponds to OG 1, ≥ 90% corresponds to OG 2, and < 90% corresponds to OG 3. Thus, OG 2 represented a neck remnant or minor interstitial filling within the coil mass, and OG 3 was assigned in lesions with substantial remnant filling. Follow-up imaging (DS angiography, MR angiography, or occasionally CT angiography) was graded at first from the reading radiologist's report, and then latterly at a departmental multidisciplinary team review (comprising both endovascular therapists and neurosurgeons). These neuroimages were compared with the most recent angiogram or the EOT DS angiography study and categorized as stable or unstable accordingly.
Endovascular Treatment Procedures
Endovascular treatments were performed to achieve complete angiographically confirmed occlusion by using platinum coils to pack the aneurysm sac as densely as possible under fluoroscopy control, using monoplane (until 2000) or biplane (Siemens, Axion) equipment. Our original technique has been described previously. 2 Since then, we have incorporated and applied new techniques as appropriate, which include the following: the use of balloon assistance, 31 stent assistance, 3D rotational angiography, and 3D reconstruction CT angiography. In patients harboring multiple aneurysms, the lesion believed to have caused the hemorrhage (that is, the target aneurysm) was treated first. Coincidental aneurysms were treated during the same procedure or subsequently, either by embolization or surgical clip ligation.
Details of Aneurysms Treated
An angiographic assessment of the aneurysm's suitability for EVT was made at the time of presentation by using DS and 3D angiography (CT angiography or rotational DS angiography). The assessment required that the neck of the aneurysm be sufficiently discrete to retain coils and that embolization could be performed without compromising the parent or adjacent arteries.
The sizes and locations of the target aneurysms are presented in Table 3 . Most aneurysms (443, 77.7%) were small (≤ 10 mm in diameter), 113 (19.9%) were large (> 10 to ≤ 25 mm), and 14 (2.5%) were giant (> 25 mm). Of the small aneurysms, 322 (72.7%) had a small neck (≤ 4 mm). The ACoA was the most common location, with 162 aneurysms (28.4%); this was followed by the PCoA with 115 aneurysms (20.2%); 118 aneurysms (21%) were located in the posterior cerebral circulation.
The target aneurysm was treated in 1 session in all but 4 patients, whose primary treatment required 2 sessions. These were performed within 14 days of SAH in 495 patients and at 15-30 days in 75 (13.2%).
Multiple aneurysms were present in 136 patients (23.9%); the site details and sizes of these coincidental aneurysms are presented in Table 4 . Twenty-one patients had 3 aneurysms; 9 patients had 4; 2 patients had 5; 3 patients had 6; and 1 patient had 7 aneurysms. In all, 198 coincidental aneurysms were diagnosed. Eighty-seven (44%) of these aneurysms were treated during the study period; 78 by coil embolization and 9 by microsurgical clip ligation.
Statistical Analysis
Follow-up periods were calculated for each patient as the number of days between the treatment date and the date of last contact. The data from these calculations were analyzed using Kaplan-Meier survival curves to acquire the probability of survival time and rupture-free survival time. The risk of rebleeding could then be assessed for each patient's follow-up year and related to the total number of patients at risk for rebleeding in that year (that is, those patients still living, not lost to follow-up review, and who had not experienced a rebleeding episode). The longest follow-up time was 5798 days (191 months), mean 2234 days (73.7 months).
Results
Clinical Outcomes
In the first 30 days postprocedure, 43 patients (7.5%) died, and 8 patients, who had been discharged from hospital in satisfactory condition, were lost to follow-up review (4 of these emigrated from the UK). During the period of 1-6 months posttreatment, 9 patients (1.6%) died of various causes unrelated to the procedure. These and subsequent deaths identified by the follow-up protocol were individually reviewed to exclude causes other than rebleeding.
For the 562 patients (100%) for whom we have follow-up information after their discharge from hospital, the clinical outcomes at 6 months were as follows: 419 patients (74.6%) made complete recoveries (GOS 1); 44 (7.8%) made good recoveries (GOS 2); 34 (6.0%) were moderately disabled (GOS 3); 13 (2.3%) were severely disabled (GOS 4); and 52 (9.3%) had died (GOS 5). These outcomes, stratified by their initial WFNS grades, are presented in Table 5 .
A high proportion of patients were classified as WFNS Grade I compared with WFNS Grade II on presentation, which we attribute to some ambiguity in their discrimination. For this reason, these 2 groups have been amalgamated for analysis. Excellent outcomes (GOS Score 1) measured at 6 months posttreatment were achieved in 86% of patients in WFNS Grades I and II, in 58.3% of patients in WFNS Grade III, and in 43.3% of patients in WFNS Grades IV and V at the time of treatment. Overall, excellent or good outcomes (GOS scores of 1 and 2) were achieved in 82.4% of patients. Death from all causes by 6 months posttreatment was 4.8% for patients in WFNS Grades I-III; 25.8% for patients in WFNS Grades IV and V; and 9.3% for all patients combined.
Angiographic Outcomes
The degrees of occlusion assessed by angiography performed immediately after coil embolization (that is, at EOT) in the 570 patients were as follows: OG 1 in 355 (62.3%), OG 2 in 183 (32.1%), and OG 3 in 32 (5.6%). This grading was used as the baseline for subsequent comparisons.
The first follow-up angiographic assessment of the degree of occlusion was made approximately 6 months after coil embolization in 452 (88.6%) of the available 510 patients (excluding those who had died or were lost to follow-up during the first 6 months). Some patients did not have an angiographic assessment because they were classified in poor grade, and it was judged inappropriate because additional treatment would not be recommended, or the patient refused (see Fig. 1 ). The findings, according to aneurysm size, are presented in Table 6 . Complete occlusion (OG 1) was maintained in 301 aneurysms (66.6%), and a neck remnant (OG 2) was observed in 129 (28.5%). Substantial remnant filling (OG 3) was present in 22 (4.9%) of the target treated aneurysms.
Aneurysm remnants (OG 2 or OG 3) were defined as stable or unstable after comparison with previous imaging. This assessment identified cases in which a change in aneurysm occlusion was not sufficient to warrant an increase in the OG level or which occurred in aneurysms that had already been classified in the worst category (that is, as OG 3). Stable occlusions were present in 74.5% of the small aneurysms, in 72.2% of the large aneurysms, and in 60% of the giant aneurysms. Overall, 333 aneurysms (73.7%) remained stable and 119 (26.3%) had enlarged to some degree. Aside from identifying recurrence rates, angiography also demonstrated improvement from the EOT occlusion grades in 34 aneurysms (7.5%; 21 small and 13 large) due to thrombosis following the reversal of periprocedural anticoagulation.
Aneurysm regrowth (that is, unstable occlusion) occurred with varying frequency and was related to the degree of aneurysm occlusion at EOT or on the last angiogram. Of the 301 aneurysms that were OG 1 initially, 252 (83.7%) remained stable (free from coil compaction and recanalization) at 6 months. In contrast, 57.4% (74 of 129) of the OG 2 and 40.9% (9 of 22) of the OG 3 aneurysms remained stable. Angiographic stability of aneurysm occlusion at 6-month follow-up imaging sessions compared with pretreatment fundus and neck sizes is shown in Fig. 2 .
In addition to the 6-month angiogram, 271 (60%) of the available 452 patients received at least 1 subsequent angiogram, and 129 patients (28.5%) received at least 3 follow-up angiograms in total. Information on the most recent angiogram is provided in Table 7 , in which we compare aneurysm stability with aneurysm size and EOT occlusion grade. The mean time from procedure to last angiographic follow-up was 37.6 months (range 2 to 179 months).
Aneurysm Retreatments
Recurrent aneurysms were retreated in 69 patients; 65 (11.4%) by EVT and 4 (0.7%) by surgical clip ligation. Two additional patients with identified recurrences were offered retreatment but refused it. Considering the EOT * There were no follow-up data for 8 people at 6 months because they either emigrated from the UK (4 patients) or they have yet to receive a 6-month follow-up examination. Of the 69 patients who were retreated for recurrence, nearly two-thirds (43, 66.2%) had been observed to have unstable occlusion on the 6-month angiogram. Importantly, one-third appeared stable at that time. The mean time from the original coil occlusion procedure to retreatment was 13.4 months (see Table 7 ).
Aneurysm Rehemorrhages
Nine patients suffered late (that is, more than 30 days after EVT) recurrent spontaneous SAH. The earliest of these events occurred 2 months after coil embolization, and the latest occurred 114 months after initial treatment. These patients were identified after readmission to the hospital or on follow-up inquiry, as described above.
Details of the patients and their aneurysms are listed in Table 8 . Rebleeding in Cases 1 and 2 was caused by the rupture of an incidental untreated aneurysm. Both treated and untreated aneurysms appeared stable on the 6-month angiogram in one patient, and the other patient had not yet had 6-month follow-up angiography. In Case 3, the rupture was caused by a small de novo aneurysm located contralateral to the treated aneurysm. This patient was retreated and discharged in good condition. The patient in Case 4 underwent treatment for a distal MCA aneurysm assumed to be the result of radiotherapy given 20 years previously to treat a recurrent middle cranial fossa epidermoid tumor. He suffered a rehemorrhage 2 months later, and angiography showed recurrence. Repeat EVT was performed, with occlusion of the aneurysm sac and parent artery. The parent artery was again patent, with a small residual aneurysm neck visible on angiography 6 months later. This appearance remained stable on subsequent follow-up angiography 2 years after the retreatment. The patients in Cases 5 and 9 were found to have some aneurysm regrowth on their 6-month follow-up angiograms; their lesions also had enlarged substantially by the time of rebleeding 13 and 85 months later, respectively.
Seven patients survived rehemorrhage and were retreated-6 by endovascular coil embolization and 1 by surgical clip occlusion (Case 6). All made good subsequent recoveries (GOS Scores 1 and 2), except 1 patient, who recovered with minor disabilities (GOS Score 3).
At initial follow-up angiography (at 6 months), 3 of the 6 recurrent (that is, target) aneurysms that rebled were judged unstable and 3 were stable. These represented 3 (2.5%) of 119 unstable and 3 (0.9%) of 333 stable treated aneurysms. Repeat SAH was especially common in aneurysms at the BA termination; that is, in 4 (44.4%) of 9 patients. The frequency of ruptured aneurysms treated at this location was 72 (12.6%) of 570 in the cohort and therefore represents a site at higher risk of repeat hemorrhage (OR 5.80, 95% CI 1.52-22.13; p = 0.01).
Long-Term Survival
The overall survival rate and number of patients at risk during each follow-up year are presented in Table 9 . The probability of death beyond Year 11 is not given because of instability in the long-term survival data, arising from the inevitability that our data on deaths are likely to be more complete than our data on continued survival for these patients with a particularly long follow-up duration. However, for completeness, we have provided the number of deaths, the number at risk, and the number of patients censored in each year from Years 12 to 16. (47) 123 (45) 22 (8) 271 (100) total retreated (%)
22 (32) 34 (49) 13 (19) 69 (100) * Follow-up angiogram corresponding to the last angiogram performed. * For patients with multiple aneurysms, the first aneurysm(s) listed was (were) the target and the one in bold was the source of the rebleeding event. Abbreviations: G/W = giant sac/wide neck; S/S = small sac/small neck; S/W = small sac/wide neck. † Stable and unstable categories were assigned at the time of the 6-month follow-up, and corresponded to coil compaction and changes in aneurysm morphology. ‡ Unstable regrowth evident at the time of retreatment.
Annual rebleeding rates varied between 0% and 0.5% in the first 9 years. Only 1 patient rebled thereafter (in their 10th year). However, this was due to rupture of a de novo aneurysm. In the first 9 years, the highest annual rebleeding rate was 0.5%, which occurred in the 1st year; although for 2 of the 3 patients who rebled in this year, the event was due to the rupture of a coincidental aneurysm. Therefore, the annual rebleeding rates from target treated aneurysms ranged from 0.2% in the 1st year to 0.4% in the 8th year (Table 10) . No further rebleeding occurred in the 138 patients who had been observed for more than 10 years at the time of our analyses, and no rebleeding was documented in patients who did not undergo follow-up angiography.
Discussion
The goal of endovascular embolization of recently ruptured intracranial aneurysms is to prevent acute rebleeding and to provide patients with stable long-term aneurysm occlusion. Although embolization has been shown to reduce the incidence of acute rehemorrhage, the stability of the occlusion in the long term and the possibility of an ongoing risk of rebleeding remain valid concerns. 5, 20, 27, 35 The single-center, single-surgeon study reported here is the largest study with the longest follow-up in the literature so far. These results benefit from consistency in protocol, technique, skill, and environment, which is not always possible at centers with multiple surgeons or in studies with multicenter data. A major strength is the relatively high proportion of patients responding to inquiries sent via the postal service, at up to 16 years after their treatment. We believe that this is possibly (at least in part) because of our practice of offering surveillance imaging and maintaining contact with patients by repeated mail inquiry. The UK's medical system also helps, because patients can be located through their National Health Service registration, and an exchange of treatment reports * Due to instability in long-term survival data, direct probability of death is not given beyond the 11th year. Abbreviations: Pts = Patients ; -= not applicable. between hospitals is encouraged. Although we have had to rely on outcome assessments that were not blinded to initial treatment, we believe that any resulting bias is mitigated by patients' self-reporting of functional outcome and internal review of follow-up imaging by multiple readers. Over the years covered by this study, there have been various technical changes in treatment and follow-up, which are reflected in the techniques used. These include the introduction of bioactive coils, stents, balloon-assisted coil occlusion, and 3D angiography, which have had a varying impact on practice and might limit the ability to make comparisons with earlier case reports. However, in our practice, only a small number of patients (fewer than 25) were treated with coated coils, and only 4 patients participated in a randomized trial of a bioactive coil (Cerecyte Coil Trial). Thus, the numbers of patients treated with coated platinum coils is too small to affect the overall results or warrant separate analysis. Other innovations were adopted as their value became apparent in practice. Balloon-assisted coil embolization was used in 73 patients (12.8%) when the aneurysm neck was too wide to hold coils. Similarly, adjuvant stents were used in 38 patients (6.7%), generally for the same reason, or when aneurysm recurrence was considered likely on anatomical grounds or during retreatment after coil compaction.
However, there have been demographic shifts over the course of this study. Comparison with our institution's report 3 published 10 years ago shows a shift in the referral pattern toward the treatment of older patients (> 60 years of age: 30.8% now vs 19.2% previously), to earlier treatment (within 48 hours of SAH: 43.7% vs 28.7%), to patients with poorer grades (WFNS Score IV and V: 21.6% vs 10.7%), and an increase in the proportion of ACA aneurysms (34.4% vs 26.2%) and decrease in BA aneurysms (14.9% vs 29.7%). These changes reflect the increased availability of EVT in our neighboring hospitals and the effect of the ISAT publication. 27 They are similar to the demographic shifts reported by other series of purely ruptured aneurysms. 40 Rates for good clinical outcomes were similar to those in our previous report (GOS Scores 1 and 2: 82.4% vs 81.4%), but the overall mortality rate increased (9.3% vs 5.1%), probably reflecting the increase in the proportion of patients with a poor grade and longer follow-up duration. This rate is lower than the 11% of patients who died within the first 5 years in the endovascular coil-treated group reported in the ISAT. 28 Several large single-center series of mixed ruptured and unruptured aneurysms have been performed to investigate the degree of long-term protection provided by coil embolization against rebleeding. [3] [4] [5] [6] [7] [8] 10, [12] [13] [14] [15] [24] [25] [26] [30] [31] [32] [33] [34] [35] [36] [37] [38] 43, 44, 48 These studies have consistently reported aneurysm recurrence and regrowth rates that are greater than rebleeding rates, 11 a finding that has been used to recommend more frequent follow-up imaging for patients with coil-occluded (vs clip-ligated) lesions.
The liability of coil-treated aneurysms to recurrence has been a consistent cause for concern; this is based largely on the assumption that it heralds rerupture or exacerbation of symptoms. Estimates of its frequency vary widely (6%-33%) and various risk factors have been described, including underpacking, wide necks, and large or giant size. 13, 16, 17, 23, 32 Centers performing the most frequent follow-up imaging have reported higher aneurysm recurrence rates. 8, 35 The wide range of reported incidences probably reflects variability in end point criteria, followup imaging protocols, and a general lack of independent evaluations. Individualized comparative imaging should be an effective way of determining if the degree of occlusion in a particular aneurysm is stable. In this study and in our previous report, 3 remnant enlargement on sequential imaging (that is, instability) was a risk factor for rebleeding and, unsurprisingly, retreatment.
Conversely, occlusion stability on 6-month (shortterm) follow-up imaging failed to predict subsequent aneurysm recurrence in one-third of our cases, and our imaging protocol has now been extended to include MR angiography studies 2 years after EVT. The risk of rebleeding after satisfactory occlusion as demonstrated at 6 months is low, and the need for such a regimen has been challenged on the basis that it is lower than the rate accepted after clip ligation, in which a less rigorous policy is standard practice. 39 Less controversial is the growing acceptance that after SAH, patients remain at increased risk of rebleeding caused by coincidental or de novo aneurysms. 46, 49 Thus, for younger patients, particularly those with coincidental aneurysms, we are now scheduling MR angiography studies at 5 and 10 years despite stable occlusions.
Unlike aneurysm recurrences, there is a narrow range of instances and greater consistency in reports regarding retreatments of coil-occluded aneurysms. A particular strength of our study is that a retreatment policy was applied consistently. The overall late endovascular retreatment rate of 11.4% (65 of 570 lesions) is similar to that reported by others. 4, 15, 21, 38 Risk factors are the same as for recurrence with additional length and frequency of follow-up imaging and younger age (which probably reflects a greater level of concern). In our study, the majority of retreated aneurysms had unstable occlusion grades on follow-up at 6 months, and they were more likely to be incompletely occluded at primary treatment. A recent large series of unselected patients reported a mean interval to retreatment of 27.2 months, and for aneurysms treated a third time, an interval of 25.3 months. 15 Similar intervals have been reported in other series, 37 which implies that recurrence occurs over a 2-year period, and that a follow-up imaging protocol of only angiography at 6 months is too short. Because only a proportion (that is, approximately 30%-56%) of coil-occluded aneurysms showing recurrence are retreated, and if rebleeding is an inevitable consequence (given sufficient time), then we are either very good at detecting and selecting those aneurysms before rebleeding occurs, or the link is less direct.
What effect retreatments have on the frequency of late rebleeding is unknown, but it is clear that a very small number of patients experience further episodes of SAH, and in some, such bleeding occurs from untreated coincidental or de novo aneurysms. Estimating the frequency of rebleeding from coil-treated aneurysms and comparing reports is hampered by the small number of events, incomplete data, and variations in reported criteria. For example, in this study 5 patients rebled 1 year after primary retreatment, and these events occurred in Years 2-8. Using this definition of late rebleeding, the ISAT investigators reported 10 events in Years 2-5 in a cohort approximately twice the size. Although rebleeding occurred in only 10 patients who received EVT and 3 who underwent clip ligation, the risk was significantly higher in the former (p = 0.02) when analyzed on the basis of treatment received. 28 The lack of subsequent rebleeding in both studies is reassuring evidence that aneurysm recurrence due to coil compaction (sufficient to provoke rebleeding) may plateau over the medium term.
In the study reported here, the overall incidence of rebleeding more than 30 days after treatment was 1.6% (or 1.1% for treated aneurysms), with a mean follow-up period of 73.7 months. We found an overall risk for rebleeding of only 0.53% (3 patients out of 570 total patients at risk) during the 1st year after coil occlusion, which included 2 episodes of rebleeding attributed to coincidental untreated aneurysms. In total, 3 of the 9 rehemorrhage events were caused by rupture of de novo or coincidental untreated aneurysms. This finding is similar to the finding in other long-term series-that the risk of rebleeding from the treated aneurysm falls as the risk from de novo aneurysms increases, with a cross-over point toward the end of the 1st decade. 45, 47, 49 The evidence is thus accumulating to support the contention that despite the high rate of incomplete anatomical cure, coil occlusion is protecting treated aneurysms from rerupture in the long term, although it is not protecting patients from the liability of developing further aneurysms.
How does the frequency compare with late rebleeding after clip ligation? Schaafsma et al. 39 followed up on a cohort of 283 patients with satisfactory occlusion on angiograms at 6 months and found only 2 reruptures in the first 8 years (0.4%). They calculated a cumulative incidence of 0.8% for coil-treated patients, and 2.6% for a matched group of patients whose aneurysms were clipped. The Cerebral Aneurysm Rerupture After Treatment study recently reported a strong association between the degree of aneurysm occlusion after coil occlusion or clip ligation, and rerupture in the short term, with an overall modestly increased risk after coil placement. 20 However, given the accepted higher incidence of delayed aneurysm recurrence after coil embolization, and ISAT rehemorrhage rates of 4.9% for coil-treated patients and 1.2% for clip-treated patients at 1 year, 29 it is hard to understand these findings unless the small number of events and some unknown factor affecting a minority of patients is distorting the results.
Conclusions
In this large and lengthy follow-up study of patients treated with endovascular coil embolization, clinical outcome and angiographic follow-up data both confirm that this treatment is a safe and efficient practice for preventing late spontaneous rebleeding. The rebleeding rates are similar to those reported in coil occlusion studies with short-and medium-term follow-up, as well as in studies of microsurgical clip ligation. Although rebleeding rates are low, recanalization was still found to be relatively common, even in aneurysms that are fully occluded following initial treatment. Even though the current finding supports the practice of frequent follow-up imaging in the medium term, the paucity of events after 8 years suggests that imaging of stable treated aneurysms is unnecessary. We are not in a position to make a recommendation regarding the risks of bleeding from de novo or unruptured coincidental aneurysms, but they do pose potentially greater risks to the individual in the long term. Because of this uncertainty, we currently recommend that patients with unruptured lesions that were coincidental to their original ruptured aneurysm be carefully monitored.
Disclosure
Dr. Byrne is supported by the Oxford Biomedical Research Centre. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Author contributions to the study and manuscript preparation include the following. Conception and design: all authors. Acquisition of data: Byrne, Plowman, A Clarke. Analysis and interpretation of data: all authors. Drafting the article: Byrne, Plowman. Critically revising the article: Byrne, Plowman, M Clarke. Statistical analysis: Plowman, M Clarke. Study supervision: Byrne.
